Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism

Brain

Volumn 128, Issue 6, 2005, Pages 1247-1258

  Williams, David R ^a,b   De Silva, Rohan ^b,c   Paviour, Dominic C ^a,d   Pittman, Alan ^b   Watt, Hilary C ^c,e   Kilford, Linda ^a,d   Holton, Janice L ^a,b,c   Revesz, Tamas ^a,c   Lees, Andrew J ^a,b,d  

^a Queen Square Brain Bank for Neurological Disorders ^*  (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Sara Koe PSP Research Centre   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Progressive supranuclear palsy; PSP; PSP P; Richardson's syndrome; Tau

Indexed keywords

APOLIPOPROTEIN E; LEVODOPA;

ADULT; AGED; ARTICLE; BODY POSTURE; DEMENTIA; DISEASE CLASSIFICATION; DISEASE DURATION; FACTORIAL ANALYSIS; FALLING; FEMALE; GAZE PARALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSONISM; PATHOLOGY; PHENOTYPE; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROGRESSIVE SUPRANUCLEAR PALSY PARKINSONISM; RICHARDSON SYNDROME; SEX RATIO; TREMOR;

AGE OF ONSET; AGED; APOLIPOPROTEINS E; CLUSTER ANALYSIS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PHENOTYPE; PONS; PROTEIN ISOFORMS; SUPRANUCLEAR PALSY, PROGRESSIVE; SYNDROME; TAU PROTEINS;

EID: 20444436764     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh488     Document Type: Article

References (68)

1. Albert ML, Feldman RG, Willis AL. The 'subcortical dementia' of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37: 121-30.
2. Arai T, Ikeda K, Akiyama H, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 2001; 101: 167-73.
3. Arnold G, Tatsch K, Oertel WH, et al. Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. J Neural Transm Suppl 1994; 42: 111-8.
4. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 84: 361-84.
5. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8: 711-5.
6. Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997; 56: 726-34.
7. Bigio EH, Brown DF, White CL. Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol 1999; 58: 359-64.
8. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002; 17: 1255-64.
9. Braak H, Jellinger K, Braak E, Bohl J. Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathol (Berl) 1992; 84: 478-83.
10. Brion JP, Couck AM, Passareiro E, Flament-Durand J. Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol 1985; 17: 89-96.
11. Brion JP, Couck AM, Robertson J, Loviny TL, Anderton BH. Neurofilament monoclonal antibodies RT97 and 8D8 recognize different modified epitopes in paired helical filament-tau in Alzheimer's disease. J Neurochem 1993; 60: 1372-82.
12. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 1999; 9: 681-93.
13. Buee L, Delacourte A, Wilhelmsen KC, Miller B, Geschwind D. Neuronal subpopulations and genetic background in tauopathies: a catch 22 story? Neurobiol Aging 2001; 22: 115-21.
14. Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 1999; 46: 325-32.
15. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997; 41: 277-81.
16. Daniel SE, De Bruin V, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995; 118: 759-70.
17. Davis PH, Bergeron C, McLachlan DR. Atypical presentation of progressive supranuclear palsy. Ann Neurol 1985; 17: 337-43.
18. de Silva R, Hope A, Pittman A, et al. Strong association of the Saitohin gene Q7 variant with progressive supranuclear palsy. Neurology 2003a; 61: 407-9.
19. de Silva R, Lashley T, Gibb G, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003b; 29: 288-302.
20. Delacourte A, Robitaille Y, Sergeant N, et al. Specific pathological Tau protein variants characterize Pick's disease. J Neuropathol Exp Neurol 1996; 55: 159-68.
21. Dubas F, Gray F, Escourolle R. [Steele-Richardson-Olszewski disease without ophthalmoplegia. 6 clinico-anatomic cases]. Rev Neurol (Paris) 1983; 139: 407-16.
22. Flament S, Delacourte A, Hemon B, Defossez A. Characterization of two pathological tau protein, variants in Alzheimer brain cortices. J Neurol Sci 1989; 92: 133-41.
23. Forman MS. Genotype-phenotype correlations in FTDP-17: does form follow function? Exp Neurol 2004; 187: 229-34.
24. Gibb GM, de Silva R, Revesz T, Lees AJ, Anderton BH, Hanger DP. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Brain Res Mol Brain Res 2004; 121: 95-101.
25. Goedert M, Jakes R, Crowther RA, Hasegawa M, Smith MJ, Spillantini MG. Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. Biochem Soc Trans 1998; 26: 463-71.
26. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084-9.
27. Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH. Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J 1991; 275: 99-104.
28. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 1998; 71: 2465-76.
29. Hanger DP, Gibb GM, de Silva R, et al. The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Lett 2002; 531: 538-42.
30. Hauw JJ, Verny M, Delaere P, Cervera P, He Y, Duyckaerts C. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett 1990; 119: 182-6.
31. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-9.
32. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70.
33. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5.
34. Jellinger K. Progressive supranuclear palsy (subcortical argyrophilic dystrophy). Acta Neuropathol (Berl) 1971; 19: 347-52.
35. Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 1991; 41: 25-30.
36. Ksiezak-Reding H, Morgan K, Mattiace LA, et al. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol 1994; 145: 1496-508.
37. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994; 42: 229-46.
38. Lieberman AP, Trojanowski JQ, Lee VM, et al. Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease. Ann Neurol 1998; 43: 259-65.
39. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996a; 47: 1-9.
40. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996b; 55: 97-105.
41. Litvan I, Grimes DA, Lang AE, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and cortico-basal degeneration. J Neurol 1999; 246 Suppl 2: II1NII5.
42. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467-86.
43. Liu WK, Le TV, Adamson J, et al. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. Ann Neurol 2001; 50: 494-502.
44. Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986; 36: 1005-8.
45. Mailliot C, Sergeant N, Bussiere T, Caillet-Boudin ML, Delacourte A, Buee L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett 1998; 433: 201-4.
46. Maraganore DM, Anderson DW, Bower JH, McDonnell SK, Rocca WA. Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota. Neurology 1999; 53: 1342-4.
47. Masliah E, Hansen LA, Quijada S, et al. Late onset dementia with argyrophilic grains and subcortical tangles or atypical progressive supranuclear palsy? Ann Neurol 1991; 29: 389-96.
48. Matsuo H, Takashima H, Kishikawa M, et al. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1991; 54: 397-400.
49. Morris HR, Gibb G, Katzenschlager R, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 2002; 125: 969-75.
50. Motoi Y, Takanashi M, Itaya M, Ikeda K, Mizuno Y, Mori H. Glial localization of four-repeat tau in atypical progressive supranuclear palsy. Neuropathology 2004; 24: 60-5.
51. Mulot SF, Hughes K, Woodgett JR, Anderton BH, Hanger DP. PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Lett 1994; 349: 359-64.
52. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003; 60: 910-6.
53. Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brain-stem nuclei to Alzheimer's disease. Ann Neurol 2001; 49: 53-66.
54. Pierot L, Desnos C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 1988; 86: 291-306.
55. Pittman AM, Myers AJ, Duckworth J, et al. The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet 2004; 13: 1267-74.
56. Revesz T, Sangha H, Daniel SE. The nucleus raphe interpositus in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Brain 1996; 119: 1137-43.
57. Richardson JC, Steele JC, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. Trans Am Neurol Assoc 1963. p. 25-9.
58. Ruberg M, Javoy-Agid F, Hirsch E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985; 18: 523-9.
59. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-72.
60. Schraen-Maschke S, Dhaenens CM, Delacourte A, Sablonniere B. Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases. Neurobiol Dis 2004; 15: 449-60.
61. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97-105.
62. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical supranuclear gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-59.
63. Suzuki M, Desmond TJ, Albin RL, Frey KA. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology 2002; 58: 1013-8.
64. Takanashi M, Mori H, Arima K, Mizuno Y, Hattori N. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res 2002; 104: 210-9.
65. Vermersch P, Robitaille Y, Bernier L, Wattez A, Gauvreau D, Delacourte A. Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement. Acta Neuropathol (Berl) 1994; 87: 572-7.
66. Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Brain 1996a; 119: 1123-36.
67. Verny M, Jellinger KA, Hauw JJ, Bancher C, Litvan I, Agid Y. Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol (Berl) 1996b; 91: 427-31.
68. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991; 337: 1158-9.